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ABSTRACT
Treatment of HER2+ breast cancer with trastuzumab is effective and combination 
anti-HER2 therapies have demonstrated benefit over monotherapy in the neoadjuvant 
and metastatic settings. This study investigated the therapeutic potential of targeting 
the BAG-1 protein co-chaperone in trastuzumab-responsive or -resistant cells. In the 
METABRIC dataset, BAG-1 mRNA was significantly elevated in HER2+ breast tumors 
and predicted overall survival in a multivariate analysis (HR = 0.81; p = 0.022). In a 
breast cell line panel, BAG-1 protein was increased in HER2+ cells and was required for 
optimal growth as shown by siRNA knockdown. Overexpression of BAG-1S in HER2+ 
SKBR3 cells blocked growth inhibition by trastuzumab, whereas overexpression of a 
mutant BAG-1S protein (BAG-1S H3AB), defective in binding HSC70, potentiated the 
effect of trastuzumab. Injection of a Tet-On SKBR3 clone, induced to overexpress 
myc-BAG-1S into the mammary fat pads of immunocompromised mice, resulted 
in 2-fold larger tumors compared to uninduced controls. Induction of myc-BAG-1S 
expression in two Tet-On SKBR3 clones attenuated growth inhibition by trastuzumab 
in vitro. Targeting endogenous BAG-1 by siRNA enhanced growth inhibition of SKBR3 
and BT474 cells by trastuzumab, while BAG-1 protein-protein interaction inhibitor 
(Thio-S or Thio-2) plus trastuzumab combination treatment synergistically attenuated 
growth. In BT474 cells this reduced protein synthesis, caused G1/S cell cycle arrest 
and targeted the ERK and AKT signaling pathways. In a SKBR3 subpopulation with 
acquired resistance to trastuzumab BAG-1 targeting remained effective and either 
Thio-2 or BAG-1 siRNA reduced growth more compared to trastuzumab-responsive 
parental cells. In summary, targeting BAG-1 function in combination with anti-
HER2 therapy might prove beneficial.
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INTRODUCTION
Amplification of the human epidermal growth 
factor receptor 2 (HER2) gene occurs in 15%–30% of 
breast cancers and results in high levels of HER2 protein 
expression [1]. This is accompanied by increased HER2 
signaling and promotes malignant cell growth and survival 
[2]. Therefore, patients whose tumors are characterized 
by HER2 gene amplification and protein overexpression 
develop a more aggressive type of cancer, which is 
associated with poor prognosis [3]. The humanized 
antibody trastuzumab, which targets the extracellular 
domain of the HER2 receptor, can prolong overall survival 
when used as a single agent [4] or when combined with 
chemotherapy [5]. However, 74% of patients with 
HER2+ metastatic breast cancer treated with trastuzumab 
monotherapy and about 50% of patients treated with 
a combination of trastuzumab with anthracycline and 
cyclophosphamide exhibit de novo resistance [5]. 
Moreover, although combination of trastuzumab with 
chemotherapy has significantly improved disease-free 
survival and overall survival in patients with early-stage 
HER2+ breast cancer, in the metastatic setting acquired 
resistance occurs within a year of initial treatment [6]. 
Treatment of patients with metastatic HER2+ breast cancer 
with trastuzumab plus lapatinib (EGF104900) provides 
overall survival advantage over lapatinib monotherapy 
[7]. Moreover, in the neoadjuvant setting treatment 
with trastuzumab plus lapatinib (Neo-ALTTO) [8] and 
trastuzumab plus pertuzumab (Neosphere) [9] results in 
improved pathological complete response. These data 
suggest that combination targeted therapies have great 
potential.
The co-chaperone protein Bcl-2-associated 
athanogene 1 (BAG-1) exists as three main isoforms 
BAG-1S, BAG-1M, and BAG-1L and is frequently 
overexpressed in breast cancer and preinvasive breast 
disease [10–13]. Clinical studies show that increased 
BAG-1 immunoreactivity is an independent predictor 
of outcome particularly in node-positive patients with 
oestrogen receptor (ER) positive breast cancer receiving 
adjuvant hormonal therapy alone and enhances the 
predictive power of IHC4 score (a combination of 
prognostic information derived from ER, PgR, Ki67, 
and HER2 immunohistochemical staining) [14–16]. 
Furthermore, BAG-1 mRNA has been incorporated as a 
prognostic biomarker in Oncotype DX [17] and PAM50 
[18] multigene assays. In breast xenograft studies, BAG-
1 overexpression drives growth of oestrogen-responsive 
ZR-75–1 breast cancer cells in an oestrogen-dependent 
manner [19]. At a cellular level BAG-1 can promote 
cancer progression which is characterized by evasion of 
apoptosis, through the emergence of chemo-resistance 
[20] and self-sufficiency in growth signals, as shown 
by growth-factor independent survival [19]. BAG-1 
influences cellular function through its interaction with 
diverse molecular targets including Bcl-2 [21], Hsc70/
Hsp70 chaperones [22], ER [14] and RAF-1 [23], a key 
downstream component of the HER2 signaling pathway. 
Although the significance of BAG-1 as a biomarker 
in ER+ breast cancer is recognized, little is known about 
the role of BAG-1 in HER2+ disease. BAG-1 protein 
levels are increased in some HER2+ breast cancer cell 
lines [10, 24], while HER2 gene transfer in MCF7 cells 
increases expression levels of BAG-1 and its interacting 
partner Bcl-2 [25, 26]. Proof-of-principle studies 
from our laboratory show that it is possible to restrict 
breast cancer cell growth by targeting BAG-1 protein-
protein interactions using synthetic peptides and small 
molecule compounds, like Thioflavin S (Thio-S) and 
its biologically potent constituent Thio-2 [27–29]. Our 
investigation adopted a multipronged strategy comprising 
overexpression, RNA interference, and protein-protein 
interaction inhibitors of BAG-1 to examine BAG-1 
function in HER2+ breast cancer cells and to explore 
whether combination of BAG-1-targeted therapies with 
trastuzumab could restrict growth of these cells more 
effectively than trastuzumab monotherapy.
RESULTS
BAG-1 mRNA and breast cancer outcome
As expression of BAG-1 protein is frequently 
increased in breast cancer [12, 14, 15, 30, 31], we 
examined whether an association might exist between 
BAG-1 mRNA levels and disease outcome. Oncomine™ 
(Compendia Bioscience, Ann Arbor, MI) was used 
to analyze BAG-1 gene expression in the Molecular 
Taxonomy of Breast Cancer International Consortium 
(METABRIC) dataset [32], comprising 1971 patients 
of which there were 506 deaths due to breast cancer. 
An unbiased estimation of the optimal cutpoint between 
patients whose tumors express BAG-1 at high and at 
low levels was performed using X-tile software [33]. 
Statistical significance for death from disease was 
determined using Kaplan-Meier (log-rank test) univariate 
analysis (Figure 1). High BAG-1 mRNA expression 
was significantly associated (p = 0.001) with improved 
prognosis in line with findings from other patient cohorts 
[15]. Furthermore, high BAG-1 expression remained an 
independent prognostic predictor (p = 0.022) of death 
from breast cancer in a multivariate model comprising 
standard clinicopathological variables (Table 1).
BAG-1 expression in HER2+ breast cancer cells
Amplification of HER2 is associated with poor 
prognosis in breast cancer [3]. To examine the association 
between BAG-1 gene expression and HER2 status the 
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METABRIC dataset was analyzed. Data revealed that 
BAG-1 mRNA was significantly increased in HER2+/
ER+ and HER2+/ER- tumors compared to normal breast 
tissue (Figure 2A). Survival data for HER2 positive 
tumours was not analyzed as a separate subgroup as we 
felt that the number of patients in the HER2 positive 
subset would not have been sufficient to achieve adequate 
statistical power for this analysis. We next examined 
BAG-1 protein immunoreactivity in a panel of breast 
cancer cell lines representing distinct disease subtypes 
and in non-tumorigenic MCF10A mammary epithelial 
cells. Immunoblot analysis showed that BAG-1 protein 
isoforms were present in all cell lines examined and 
densitometric analysis revealed that total BAG-1 levels 
were higher in HER2-overexpressing cells (Figure 2B), 
in concordance with the METABRIC patient data 
(Figure 2A). To determine the functional significance of 
BAG-1 expression in breast cancer, the effect of BAG-1 
knockdown by siRNA (siBAG-1) on cell growth was 
examined in the breast cancer cell line panel. Robust 
knockdown of BAG-1 protein isoforms was achieved 
(72%–86%; Figure 2C) and was sustained for at least 
8 days post-transfection (data not shown). Following 
siBAG-1 treatment, growth of HER2-overexpressing 
MDA-MB-453 was slightly reduced, while that of 
SKBR3 and BT474 was significantly reduced compared 
to siRNA nonsense control sequences (NSC) (Figure 2C). 
Moreover, growth of ER+ T47D cells was significantly 
reduced, while there was a small but not significant 
reduction in the growth of MCF7 cells. Triple negative 
CAL51 and MCF10A non-tumorigenic cells remained 
unaffected (Figure 2C). Under these conditions, growth 
of ZR-75–30 and BT20 cells was adversely affected by 
NSC control thereby precluding meaningful interpretation. 
Taken together, these data suggest that BAG-1 may have 
a prosurvival role in HER2+ cells and further justifies 
investigating the impact of BAG-1 on the sensitivity of 
HER2+ cells to trastuzumab and the potential of BAG-1 
as a therapeutic target in HER2+ breast cancer. 
Effect of BAG-1 overexpression and knockdown 
on the growth of HER2+ cells treated with 
trastuzumab
To investigate the possibility that targeting BAG-1 
protein function in HER2+ cells could influence response 
to trastuzumab, BAG-1S, which has previously been 
shown to protect MCF7 cells from a variety of stresses 
[20], was overexpressed in SKBR3 HER2+ cells as 
verified by immunoblot analysis (Figure 3A); an empty 
Figure 1: Kaplan-Meier analysis for breast cancer specific survival in the METABRIC cohort. High BAG-1-censored (|), 
low BAG-1-censored (|).
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vector was transfected as a control (Figure 3A). HER2 
expression levels remained unchanged 96 h post-
transfection in control and BAG-1S transfected cells 
(Figure 3A). Although treatment with trastuzumab resulted 
in 70% reduction in the long-term growth of control cells 
(Figure 3A) this was inhibited by overexpression of BAG-
1S, as reflected by the similar level of growth observed 
between untreated and trastuzumab-treated BAG-1S 
overexpressing cells (Figure 3A). These data suggest that 
BAG-1S overexpression can inhibit the growth-inhibitory 
effect of trastuzumab. 
We also examined whether response to trastuzumab 
could be influenced by BAG-1 protein interactions. To 
this end, a BAG domain helix 3 mutant (Q201A/D208A/
Q212A) BAG-1S protein (BAG-1S H3AB), which is 
defective in binding HSC70 [34], was overexpressed 
in SKBR3 cells as confirmed by immunoblot analysis 
(Figure 3A). Studies using a series of BAG-1 deletion 
mutants have shown that although helix 3 of the BAG 
domain, the region within which the H3AB mutation 
occurs, mediates interaction with HSP70 it does not 
appear to be important for interaction with RAF-1 [23]. 
Overexpression of BAG-1S H3AB did not affect HER2 
protein expression but resulted in 50% growth reduction 
in response to trastuzumab compared to untreated cells 
(Figure 3A). These data suggest that growth inhibition by 
trastuzumab relies in part on the interaction of BAG-1S 
with HSC70 protein chaperones.
We reasoned that a reduction of BAG-1 protein 
expression would potentiate the growth-inhibitory effect 
of trastuzumab. SKBR3 and BT474 cells, which have 
high endogenous BAG-1 expression (Figure 2B) and 
whose growth is susceptible to targeting with siBAG-1 
(Figure 2C), were selected to address this. Immunoblot 
analysis revealed that siBAG-1 resulted in a marked 
decrease in BAG-1 expression levels compared to NSC 
but had no effect on HER2 expression (Figure 3B). In 
addition, BAG-1 knockdown resulted in ~25% decrease 
in the growth of both SKBR3 and BT474 cells relative 
to NSC (Figure 3C). When combined with trastuzumab, 
siBAG-1 caused a further ~20% reduction in growth in 
both cell lines compared to trastuzumab+NSC control 
(Figure 3C). 
As transient transfections can lead to heterogeneous 
and unsustained protein expression, we generated a 
SKBR3 Tet-On myc-BAG-1S inducible cell line in order 
to further corroborate the protective role of BAG-1 in 
response to trastuzumab; a myc tag was chosen in order 
to differentiate overexpressed from endogenous BAG-1S. 
Two clones were generated which fortuitously exhibited 
differential basal (-Doxycycline) levels (Figure 3D) 
enabling us to examine the effect of basally overexpressed 
BAG-1S on cell growth. Addition of doxycycline resulted 
in upregulation of myc-BAG-1S protein expression but 
did not affect HER2 protein levels (Figure 3D). Growth 
rate correlated with the level of BAG-1S overexpression 
in both induced and uninduced conditions. In the absence 
of doxycycline, clone 10 grew faster than clone 11 
(Figure 3E). Upon induction with doxycycline clone 
11 grew faster, relative to its corresponding uninduced 
control, versus clone 10 which exhibited higher BAG-1S 
basal expression levels (Figure 3D and 3E). Increased 
expression of BAG-1S therefore results in significantly 
increased SKBR3 growth rate.
Effect of BAG-1 overexpression on the growth of 
HER2+ mammary xenografts
To investigate the role of BAG-1 in HER2+ 
tumorigenesis in the breast, Tet-On myc-BAG-1S 
inducible clone 11 or parental SKBR3 cells were 
injected into the mammary fat pads of mice that received 
Table 1: Multivariate analysis of death from breast cancer in the METABRIC cohort comprising 
standard prognostic markers including BAG-1 mRNA levels 
Exploratory variable Hazard ratio 95% CI of HR P value
BAG-1 status 
(positive or negative)
0.81 0.67–0.97 0.022
Tumor size 
(T1, T2, T3)
1.56 1.33–1.84 < 0.001
Lymph node status 
(positive or negative)
2.14 1.76–2.60 < 0.001
Tumor grade 
(1, 2, 3)
1.32 1.11–1.56 0.001
ER status 
(positive or negative)
0.75 0.61–0.93 0.0076
HER2 status 
(positive or negative)
1.42 1.17–1.74 < 0.001
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doxycycline-supplemented (induced) or normal water 
(uninduced) and were allowed to form tumors over 
32 days. Induced Tet-On myc-BAG-1S tumors were 2-fold 
larger (mean ± SD: 18.0 ± 6.2 mm3 vs 9.1 ± 3.5 mm3) 
(Figure 4A) than uninduced controls. A comparison 
between doxycycline-treated Tet-On myc-BAG-1S and 
parental SKBR3 tumors, to account for the net effect 
of the inducer on the cells, revealed a 5.5-fold increase 
in size (mean ± SD: 3.3 ± 0.8 mg vs 18 ± 6.2 mg) 
(Figure 4A). Haematoxylin and eosin staining revealed 
that both induced and uninduced tumors exhibited poorly 
differentiated architecture (Figure 4B). Immunoreactivity 
of myc-BAG-1S appeared granular, localised to the 
cytoplasm, and was overall greater in the induced setting 
(Figure 4B). Staining for pancytokeratin, Ki67, and 
platelet endothelial cell adhesion molecule 1, a marker 
indicating mouse vasculature formation within the tumor, 
was present at a similar intensity in the area around the 
centre of all tumors examined (data not shown). These 
data suggest that increased expression of BAG-1S in 
HER2+ SKBR3 cells promotes tumor growth in vivo.
We next examined the effect of trastuzumab on 
the growth of SKBR3 cells in vitro. When treated with 
trastuzumab, growth of doxycycline-induced clones 10 
and 11, which overexpress myc-BAG-1S (See Figure 3D), 
was greater than that of uninduced controls and correlated 
with the level of BAG-1S overexpression, as clone 10 
exhibited overall significantly more growth than clone 
11 cells (Figure 4C). These data suggest that induction of 
BAG-1S overexpression attenuates growth inhibition by 
trastuzumab in vitro.
Effect of combining BAG-1-targeting therapies 
with trastuzumab on HER2+ cell growth
As BAG-1 knockdown by siRNA enhanced the 
growth-inhibitory effect of trastuzumab, we examined 
whether using Thio-S (a mixture of compounds) and its 
biologically potent constituent Thio-2, which have been 
shown to inhibit BAG-1 protein-protein interactions 
[27, 29], would have a similar effect. To reduce any 
potential non-specific effects of the compounds targeting 
BAG-1 and to keep the concentration of compound diluent 
(DMSO) in culture to a minimum, we used a 4-fold lower 
concentration than previously reported [27, 29] based on 
compound titrations we performed. Treatment of SKBR3 
or BT474 cells with trastuzumab and Thio-2 combination 
resulted in significantly reduced growth compared to 
single compound treatments (Figure 5A); the effect 
of trastuzumab+Thio-2 was overall more pronounced 
Figure 2: HER2 overexpression upregulates BAG-1 protein expression, while BAG-1 knockdown attenuates growth 
in HER2+ breast cancer cells. (A) Bar graph of the METABRIC data set shows the mean ± SEM BAG-1 mRNA expression in 
HER2+/ER+ and HER2+/ER- breast tumors and in normal breast tissue. One-way ANOVA with Holm-Sidak multiple comparisons test 
was used for comparison between different groups; *p < 0.05, ****p < 0.0001. (B) A representative immunoblot shows endogenous 
HER2 and BAG-1 expression in a panel of breast cancer cell lines representing different disease subtypes; β-actin was used as a loading 
control. Densitometric analysis of immunoblots from 3 independent experiments was used to determine expression of total BAG-1 protein 
which is expressed on the bar graph as a percentage of the maximal value ± SD. (C) Effect of nonsense control (NSC) and BAG-1 siRNA 
(siBAG-1; 50 nM) knockdown on the growth of breast cancer cell lines 6 days post-transfection. Data shown on the top graph are the 
mean ± SEM from 3 independent experiments, each with three technical replicates. Unpaired t-test was used for comparison between NSC 
and siBAG-1 treatments for each cell line; *p < 0.05, ***p < 0.001. Densitometric analysis of immunoblots from those experiments was 
used to determine total BAG-1 protein expression following siRNA knockdown and is expressed on the bottom graph as a percent of the 
corresponding NSC treatment for each cell line ± SD.
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compared to trastuzumab+Thio-S. Treatment of SKBR3 
or BT474 with a combination of Rituximab (a humanised 
anti-CD20 antibody used here as control for antibody-
dependent cellular cytotoxicity) with Thio-2 or Thio-S, 
had no additional effect on growth than either of those 
BAG-1 inhibitors used in isolation (data not shown).
To examine the enhanced growth inhibition 
observed in response to BAG-1 and HER2 targeted 
therapies, cells were treated with increasing 
concentrations of single compounds or compound 
combinations at a constant ratio. Statistical analysis 
of the efficacy of compound interactions revealed a 
synergistic mode of action for both trastuzumab+Thio-S 
and trastuzumab+Thio-2 combinations, in BT474 and 
SKBR3 HER2+ but not in MCF7 HER2- cells. In 
particular, BT474 were more susceptible than SKBR3 in 
response to Thio-2 treatments (Figure 5B). To elucidate 
the nature of this synergy at the protein signaling level, 
immunoblot analysis was performed to examine the 
molecular changes that occur when targeting BAG-1 
and HER2 in BT474 cells; compound treatments were 
applied for 24 h, similarly to studies by other groups [35]. 
Treatment with trastuzumab alone resulted in a decrease 
in the phosphorylation of HER2, AKTSer473, ERK, p70 
S6 kinase (S6K), and ribosomal S6 protein (Figure 5C). 
Moreover, phosphorylation of ERK and S6 was 
noticeably reduced by Thio-2 treatment alone and no clear 
difference with Thio-S alone was observed. Additionally, 
phosphorylation of AKTSer473 was slightly reduced by 
Thio-2 (Figure 5C). Single treatment with either Thio-2 
Figure 3: BAG-1 overexpression attenuates the growth inhibitory effect of trastuzumab while BAG-1 knockdown 
potentiates the effect of trastuzumab. (A) A representative immunoblot shows BAG-1 and HER2 protein expression in SKBR3 cells 
96 h post-transfection with the indicated constructs; β-actin was used as a loading control. Bar graph shows the effect of trastuzumab (8 μg/ml) 
on the long-term growth potential of SKBR3 cells transfected with vector control (pcDNA3) or pcDNA3 containing BAG-1S or BAG-1S 
H3AB (BAG domain mutant incapable of interacting with HSC70). Transfectants were maintained in complete media supplemented with 
G418 for 2 weeks. Data on the bar graph show the mean ± SD and are representative of two independent experiments, each with three 
technical replicates. Unpaired t-test was used for comparison between different treatments; **p < 0.01, ***p < 0.001. (B) A representative 
immunoblot shows BAG-1 and HER2 expression levels in SKBR3 and BT474 cells 3 days following siRNA (50 nM) knockdown; β-actin 
was used as a loading control. Densitometric analysis of immunoblots from 3 independent experiments was used to determine expression 
of total BAG-1 protein and is expressed as a percentage of the maximal value. The amount of BAG-1 protein knockdown by siBAG-1 is 
expressed as a percentage of the corresponding NSC treatment for each cell line. (C) SKBR3 and BT474 cells transfected with NSC or 
siBAG-1 were grown for 5 days with or without trastuzumab (32 μg/ml) and cell growth was measured using crystal violet assay. Data are 
the mean ± SEM from 4 independent experiments, each with three technical replicates. Unpaired t-test was used for comparison between 
different treatments; *p < 0.05, **p < 0.01, ***p < 0.001. (D) A representative immunoblot shows induction of Tet-On myc-BAG-1S using 
an anti-myc antibody in SKBR3 cell clones 10 and 11 48 h after addition of doxycycline (2 μg/ml); β-actin was used as a loading control. 
(E) Line graph shows the effect of BAG-1S induction by doxycycline (2 μg/ml) on cell growth over 9 days using crystal violet assay. Data 
shown on the graph are the mean ± SEM from 3 independent experiments, each with three technical replicates. Unpaired t-test was used for 
comparison between doxycycline induced and uninduced cells; ***p < 0.001. 
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or Thio-S caused a marked upregulation of AktThr308 and 
S6K phosphorylation compared to DMSO control, while 
trastuzumab+Thio-2 combination treatment caused a 
reduction in the phosphorylation of AKTSer473/Thr308, ERK, 
S6K, and S6 compared to trastuzumab+DMSO control 
(Figure 5C). In comparison, trastuzumab+Thio-S caused 
a smaller reduction in the phosphorylation of AKTThr308, 
ERK, and S6 but had no effect on AKTSer473 compared to 
trastuzumab+DMSO control. Furthermore, as shown on 
the immunoblot in Figure 5C, cell treatment with single 
compounds or compound combinations led to a noticeable 
increase in the expression levels of p27Kip1, an inhibitor of 
G1/S cell cycle transition [36], which was greatest in the 
presence of Thio-2. 
Analysis of cell cycle using propidium iodide 
staining was therefore performed to elucidate the growth-
inhibitory effect observed in response to combination 
treatment targeting BAG-1 and HER2. Results show 
that trastuzumab caused G1/S arrest in BT474 cells, 
while Thio-2 treatment exhibited greater growth arrest 
(Figure 5D). A further increase in G1/S arrest was 
observed when trastuzumab and Thio-2 were used in 
combination. Thio-S did not induce G1/S arrest on its own 
but caused slightly more G1/S arrest when combined with 
trastuzumab compared to control (trastuzumab+DMSO) 
(Figure 5D). There was no sub-G1 cell fraction, an 
indicator of cell death, detected in any of the examined 
conditions (data not shown).
S6 protein is an indispensable component of the 
40S ribosomal subunit, and is thought to be involved 
in regulating translation [37]. Based on the changes we 
observed on S6 phosphorylation in response to treatment, 
we further investigated the effect of targeting HER2 and/
or BAG-1 on global protein biosynthesis by 35S metabolic 
labelling of BT474 cells. Treatment with trastuzumab, 
Thio-2, or Thio-S reduced protein synthesis compared to 
controls (Figure 5E). When compared to single compound 
treatments trastuzumab+Thio-2 combination significantly 
attenuated translation, while trastuzumab+Thio-S 
treatment had a similar but less pronounced effect 
(Figure 5E). Overall, these data show that combining 
trastuzumab with the BAG-1 protein-protein interaction 
inhibitor Thio-2 synergistically reduces growth of BT474 
cells through suppression of ERK and AKT signaling 
pathways and leads to a reduction in global protein 
synthesis and G1/S arrest (Figure 5F). 
Effect of BAG-1 inhibition on trastuzumab-
resistant cells
We next addressed whether BAG-1 targeting 
might be of benefit in cases where acquired resistance 
to trastuzumab has developed. To this end, we examined 
the effect of targeted BAG-1 therapies on the growth 
of trastuzumab-resistant SKBR3 cells characterized by 
Nahta et al. [35] in which insulin growth factor receptor 1, 
Figure 4: Inducible expression of BAG-1S promotes growth of SKBR3 HER2+ tumors in the mouse breast. (A) SKBR3 
parental and Tet-On myc-BAG-1S clone 11 cells were injected as a PBS:Matrigel (1:1) suspension into the mammary fat pads of NOD.
SCID mice, which were given doxycycline-containing (+Doxycycline; 200 μg/ml) or plain water (-Doxycycline, control) ad libitum, and 
were allowed to form tumor xenografts over 32 days. Data shown on the bar graph are the mean ± SD tumor volume from 3 independent 
experiments. Unpaired t-test was used for comparison between different groups; ***p < 0.001. (B) Representative examples of SKBR3 Tet-On 
myc-BAG-1S xenografts to illustrate haematoxylin and eosin (H & E) tumor staining and immunohistochemical staining for myc-BAG-1S 
in the presence (+Doxycycline) or absence (-Doxycycline) of inducer following 32 days of growth in the mammary fat pads of mice. Black 
and blue size bars represent 500 μm and 20 µm respectively. (C) Effect of trastuzumab (32 μg/ml) on the growth of doxycycline-induced 
(+Doxycycline; 2 μg/ml) or uninduced (-Doxycycline) Tet-On SKBR3 myc-BAG-1S clones after 5 days of treatment using crystal violet 
assay. Data shown are the mean ± SEM of a representative experiment with three technical replicates; similar results were obtained in a 
second experiment. One-way ANOVA with Holm-Sidak multiple comparisons test was used for comparison between different groups; 
*p < 0.05, ***p < 0.001.
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Figure 5: Synergistic effect of targeting BAG-1 and HER2 on breast cancer cell growth and signaling. (A) SKBR3 and 
BT474 cells were treated for 5 days with DMSO (0.125% v/v), trastuzumab (16 μg/ml), Thio-S (12.5 μM), Thio-2 (12.5 μM) or combinations 
of these compounds, as indicated. Cell growth was measured using crystal violet assay and is expressed as a percentage of untreated cells. 
Data shown on the graph are the mean ± SEM from 3 independent experiments, each with three technical replicates. Statistical significance 
was determined using two-way ANOVA with Holm-Sidak multiple comparisons test. *p < 0.05, ***p < 0.001. (B) MCF7, SKBR3 
and BT474 cells were treated over 5 days with increasing concentrations of Thio-S, Thio-2, and/or trastuzumab at a constant ratio. Cell 
growth was measured by crystal violet assay and is expressed as a percentage mean ± SEM of untreated cells. Combination indexes were 
determined by CalcuSyn v2.11; values < 1 indicate synergism. (C) A representative immunoblot of 3 independent experiments shows the 
effect of single compounds and compound combinations (concentrations listed in Figure 5A), 24 h after treatment, on the phosphorylation 
and expression levels of molecules involved in growth factor signaling and translation/cell cycle control downstream of HER2 and BAG-1; 
β-actin was used as a loading control. (D) BT474 cells were treated with single compounds or compound combinations (concentrations 
listed in Figure 5A) for 48 h and were subsequently harvested and stained with propidium iodide for cell cycle analysis (20,000 events/
sample) using ModFit LT v4.1.7. Bar graph shows the proportion of cells in each phase of the cell cycle as a percentage of the total number 
of cells stained. Paclitaxel (100 nM) treatment for 24 h was used as a positive control for cell cycle arrest. Data are representative of 
three independent experiments. (E) BT474 cells were metabolically labelled with 35S to quantify global protein synthesis following 24 h 
treatment with the compounds indicated (concentrations listed in Figure 5A). 35S incorporation corresponding to the total amount of protein 
synthesis is expressed as a percentage of diluent control. Data shown on graph are the mean ± SEM from 3 independent experiments, each 
with three technical replicates. Unpaired t-test was used for comparison between different treatments; *p < 0.05. (F) Simplified schematic 
diagram of PI3K/AKT and RAF/MEK/ERK signaling pathways downstream of HER2 and BAG-1. Red arrows indicate the molecular 
changes which occur as a result of combining trastuzumab with Thio-2, an inhibitor of BAG-1 protein-protein interactions.
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a protein associated with resistance to trastuzumab [38], 
interacts with and modulates the activity of HER2. Parental 
cells responded to trastuzumab by a ~20% reduction in 
growth compared to untreated control (Figure 6A); a 
further reduction in growth was observed in response to 
trastuzumab+Thio2 and trastuzumab+Thio-S combination 
therapies compared to single treatments with trastuzumab, 
Thio-2, or Thio-S (Figure 6A). As expected, trastuzumab-
resistant cells were unresponsive to trastuzumab but 
responded significantly more to Thio-2 than parental cells 
(Figure 6A); combination treatment (trastuzumab+Thio-2) 
did not reinstate sensitivity to trastuzumab.
To corroborate these findings and examine the 
role of BAG-1 in the long-term growth potential of 
trastuzumab-resistant cells, a siRNA knockdown approach 
was used. Following siRNA transfection, viable parental 
or trastuzumab-resistant SKBR3 cells were allowed 
to grow over 2 weeks. Immunoblot analysis revealed 
approximately 70% knockdown in BAG-1 protein levels 
(Figure 6B). Quantification of long-term growth showed 
that trastuzumab-resistant cells were more susceptible 
to treatment with siBAG-1, as indicated by a reduction 
in their overall growth, compared to similarly treated 
parental cells (Figure 6C). Altogether, our data suggest that 
BAG-1 can partially support growth of these trastuzumab-
resistant cells. Targeting BAG-1 might therefore constitute 
a potential therapeutic option for HER2+ breast cancers 
refractory to trastuzumab.
DISCUSSION
In this study we show for the first time that 
elevated BAG-1 protein expression correlates with 
that of HER2, is important for optimal growth of some 
HER2-overexpressing breast cancer cells, and impedes 
the growth-inhibitory effect of trastuzumab. Moreover, 
inducible overexpression of BAG-1S results in the growth 
of larger poorly differentiated HER2+ tumor xenografts 
in the mammary fat pads of mice, while induction of 
BAG-1S expression in in vitro culture attenuates growth 
inhibition by trastuzumab. Combination treatment 
targeting BAG-1 with small molecule protein-protein 
interaction inhibitors and HER2 with trastuzumab 
synergistically reduces breast cancer cell growth, which 
is accompanied by attenuation of protein synthesis and 
induction of G1/S cell cycle arrest through the ERK and 
AKT pathways. 
Analysis of the METABRIC patient cohort [32] 
revealed that BAG-1 mRNA is increased in HER2+/
ER+ as well as HER2+/ER- breast tumors compared to 
normal breast epithelium, and in HER2+ cell lines BAG-1 
protein expression is elevated. The observed increase in 
BAG-1 expression in HER2+ breast cancer cells raised 
the possibility that certain HER2+ cells may be dependent 
on BAG-1 for growth in response to the HER2-targeted 
therapy trastuzumab. Knocking down BAG-1 expression 
by siRNA confirmed that SKBR3 and BT474 HER2+ cell 
lines require BAG-1 for optimal growth. Based on this 
finding and the fact that induction of BAG-1 expression 
leads to the formation of larger xenografts in the mammary 
fat pads of mice, we hypothesized that these tumors may 
be more resistant to trastuzumab therapy depending on the 
level of BAG-1 expression. In support of this, we present 
evidence from in vitro culture experiments showing 
that induction of BAG-1S expression in two SKBR3 
cell clones leads to an increase in their growth rate and 
impedes growth inhibition by trastuzumab in a manner 
that correlates with the level of BAG-1S overexpression. 
Moreover, overexpression of BAG-1S offered protection 
in long-term SKBR3 cell cultures after transient exposure 
to trastuzumab, suggesting that upregulation of BAG-1 
may be a way by which cells could develop resistance to 
this drug. This protection is partly due to the interaction 
between BAG-1S and HSC70/HSP70 as a BAG domain 
helix 3 mutant (BAG-1S H3AB), which is deficient 
in chaperone binding, is sensitive to treatment with 
trastuzumab. These findings are in agreement with data 
published previously by our group showing that BAG-1S 
overexpression prevents heat shock-induced long-term 
growth inhibition in MCF7 cells through its interaction 
with HSC70/HSP70 protein chaperones [20]. Our proof-
of-principle data show that attenuating endogenous BAG-1 
expression by siRNA in HER2+ cells which are partly 
dependent on it for growth further increases the growth-
inhibitory effect of trastuzumab. Our data indicate that 
BAG-1 overexpression can support growth of HER2+ 
breast cancer cells and reduces the growth-inhibitory 
effect of trastuzumab both in short and long-term cultures. 
In contrast, targeting endogenous BAG-1 function with 
siRNA impedes growth of these cells and potentiates the 
growth-inhibitory effect of trastuzumab. These results 
provide a rationale for assessing BAG-1 as a biomarker of 
therapeutic response in clinical studies of breast cancers 
treated with trastuzumab. 
Based on our current data and previous findings 
[20, 27, 29] from our group we hypothesised that using 
Thio-S or Thio-2 inhibitors of BAG-1 protein-protein 
interactions in combination with trastuzumab, a first-
line treatment for HER2+ breast cancer [4], would 
further restrict growth of HER2+ breast cancer cells. The 
synergistic growth-inhibitory effect observed at the dose 
used suggested that the prosurvival function of BAG-1 
and HER2 may be exerted on distinct but functionally 
convergent signaling pathways. BAG-1 is known to 
activate RAF [23] and we have previously reported [29] 
that Thio-2 acts at the level of RAF to disrupt BAG-1 
protein-protein interactions (Figure 5F). Here, we found 
that single Thio-2 treatment markedly inhibited ERK but 
had comparatively little effect on AKT activity leading 
to attenuation of HER2+ breast cancer cell growth. 
Phosphorylation of ERK was slightly reduced with 
trastuzumab treatment. Studies have shown that allosteric 
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inhibition of ERK activity exerts a minimal effect on 
the proliferation of trastuzumab-sensitive SKBR3 and 
BT474 cells [39] and suggest that the growth-inhibitory 
effect observed is predominantly driven through the PI3K/
AKT signaling pathway leading to a decrease in S6Ser235/236 
phosphorylation and induction of cell cycle arrest. BAG-1 
targeting caused compensatory activation of AKT by 
phosphorylation at Thr308, which is known to be regulated 
by PDK1 [40], and resulted in increased S6K activity, 
which is crucial for protein synthesis and cell cycle 
progression [41]. As there was little change on AKTSer473 
phosphorylation under these conditions, it is less likely 
that the observed AKTThr308 phosphorylation was caused 
by mTOR, a key activator of AKT [42]. It is conceivable 
that this may have been caused by increased activation 
of HER2, since combination of BAG-1 inhibitors with 
trastuzumab resulted in a reduction of AKTThr308 and 
S6KThr389/412 phosphorylation to basal levels. Our data 
are consistent with other studies showing that when 
used as single agents for cancer therapy, MEK inhibitors 
frequently lead to increased AKT phosphorylation by 
relieving a negative feedback loop of ERK on HER-
family receptor signaling, which can result in reduced 
efficacy [43]. Moreover, trastuzumab caused G1/S cell 
cycle arrest that was augmented in the presence of Thio-2 
but not Thio-S. This is in line with our previous findings 
[29] showing increased potency of Thio-2 over Thio-S at 
inhibiting the interactions between BAG-1 with HSC70 
and BAG-1 with RAF. This ability of Thio-2 may account 
for the increased growth inhibition of HER2+ cells.
Our investigation reveals a protective role for 
BAG-1 in HER2+ breast cancer and provides insight 
into the mechanism by which increased BAG-1 protein 
expression supports cell viability by attenuating the 
growth-inhibitory effect of trastuzumab. Combining 
BAG-1- and HER2-targeted therapies synergistically 
inhibits HER2+ breast cancer cell growth, while 
interfering with BAG-1 function targets trastuzumab-
resistant cells more effectively. The concept of targeting 
BAG-1, a protein that supports cancer cell survival 
but is also related to improved patient survival, may 
on the surface seem paradoxical. Nevertheless, these 
observations are not mutually exclusive; since BAG-1 
enhances ER transcription and can stimulate ER activity 
[14], it would be expected to support growth of breast 
cancers that are reliant on BAG-1 related pathways. 
This is similar to the ER in ER+ breast cancer where 
its expression is associated with good prognosis [44], 
whilst the ER remains an excellent target for hormonal 
therapy, for example with tamoxifen. A few clinical 
implications can be drawn from this study. BAG-1 
could be a candidate predictive biomarker by enabling 
the definition of breast cancer patient subgroups likely 
to display de novo resistance to trastuzumab. Moreover, 
our data indicate that disrupting BAG-1 function might 
be a useful therapeutic strategy for targeting HER2+ 
breast cancers in combination with trastuzumab, but also 
for those cancers that are refractory to trastuzumab, and 
emphasise the need for developing drug-like BAG-1 
inhibitors and/or testing the efficacy of existing inhibitors 
of BAG-1 mediated pathways.
Figure 6: Trastuzumab-resistant SKBR3 cells are sensitive to BAG-1 inhibition. (A) SKBR3 parental or trastuzumab-resistant 
cells were treated over 5 days with DMSO (0.5% v/v), trastuzumab (32 μg/ml), Thio-S (50 μM), Thio-2 (50 μM), or combinations of these 
compounds as indicated. Cell viability was measured using crystal violet assay and is expressed as a percentage of DMSO control. Data 
shown on the graph are the mean ± SEM from 3 independent experiments, each with three technical replicates. Statistical significance 
was determined using two-way ANOVA with Holm-Sidak multiple comparisons test. *p < 0.05. (B) A representative immunoblot shows 
BAG-1 and HER2 expression levels in SKBR3 parental and trastuzumab resistant cells 4 days following siRNA (50 nM) knockdown. 
Densitometric analysis of immunoblots from 3 independent experiments was used to determine expression of total BAG-1 protein and is 
expressed as a percentage of untreated SKBR3 parental cells. The amount of BAG-1 protein knockdown by siBAG-1 is expressed as a 
percentage of the corresponding NSC treatment for each cell line; β-actin was used as a control for loading. (C) Bar graph shows the effect 
of BAG-1 knockdown by siRNA (50 nM) on the long-term growth potential of SKBR3 parental or trastuzumab-resistant cells. Data shown 
on graphs are the mean ± SEM from 3 independent experiments, each with 3 technical replicates. Unpaired t-test was used for comparison 
between different treatments; **p < 0.01.
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MATERIALS AND METHODS
Cell culture and treatments
All cell lines were purchased from LGC Standards 
(UK), while CAL51 were purchased from DSMZ 
(Germany); cell lines were grown as recommended by 
their suppliers. SKBR3 Tet-On myc-BAG-1S inducible 
clones were maintained in DMEM containing 10% (v/v) 
tetracycline-free FCS (Biosera, France), 2 mM L-Glutamine, 
penicillin (100 units)/streptomycin (100 μg/ml), 
and blasticidine/zeocin for selection. Expression of myc-
BAG-1S was induced by doxycycline (2 µg/ml). MCF10A 
cells were cultured as described by Debnath et al. [45]. 
SKBR3 parental and trastuzumab-resistant (clone 3) cells 
were kindly provided by Professor Francisco Esteva (M. D. 
Anderson Cancer Center, USA) and cultured as previously 
described [35]. All cells were maintained at 37°C in a 10% 
CO
2
 humidified atmosphere. Thioflavin S (Thio-S) practical 
grade was from Sigma (UK) and Thio-2 was produced at 
the Institute of Pharmacy/Pharmacognosy, University of 
Innsbruck as described previously [29]. Trastuzumab was 
gifted by the Oncology Pharmacy at Southampton General 
Hospital. 
Expression constructs
pcDNA3-BAG-1S wt and H3AB mutant constructs 
were generated as described previously by our group 
[14, 34]. An inducible Tet-On myc-BAG-1S construct 
was generated by touchdown PCR amplification [46] using 
primers: 5ʹ- ATTAAGCTTGCCA CCATGGAACAGAA 
ACTGATCTCTGAAG AAGACCTGAATCGGAGCCAG 
GAGGTGACCC and 5ʹ- CCGCTCGAGCTGCTACACCT 
CACTCGG CCAG and subsequent ligation of the resulting 
amplicon into a pcDNA4/TO plasmid (T-REx System, 
Invitrogen, UK) with HindIII and XhoI flanking sites.
Cell transfection
Expression constructs were transfected using Fugene 
HD (Promega, UK) according to the manufacturer’s 
instructions. ON-TARGETplus SMARTpool BAG-1 
siRNA or siRNA nonsense control sequences (GE 
Healthcare Dharmacon, UK) were transfected by 
DharmaFECT 1 reagent according to the manufacturer’s 
protocol. Cells were seeded for experiments 24 h post-
transfection. To generate Tet-On inducible clones, 
pcDNA4/TO-myc-BAG-1S:pcDNA6/TR (T-REx™ 
System, Life Technologies, UK) vectors were co-
transfected into SKBR3 cells and individual clones were 
isolated following blasticidine/zeocin selection.
Cell growth assays
The effect of drugs on cell survival was determined 
by crystal violet assay. Briefly, 1,000–10,000 cells/well 
were seeded in triplicate in 96 well plates (Corning, 
USA) for short-term (4–5 days) cell viability or in 
12 well plates for long-term growth assays, as described 
by Townsend et al. [20], and treated as described in the 
text or figure legends. Uninduced or doxycycline-induced 
cells were allowed to grow for a further 24 h prior to 
treatment. Following treatment, media were removed and 
monolayers fixed in 4% paraformaldehyde (pH 7.4) for 
30 min and stained with 0.5% crystal violet for 20 min. 
Plates were rinsed in a water bath and dried. Growth 
was expressed as a measure of the adherent cells by 
extracting the associated dye with 10% (v/v) acetic acid 
and reading the absorbance at 590 nm with a Varioskan 
Flash multimode reader (Thermo Scientific, UK). Long-
term growth was measured using ColonyArea ImageJ 
(1.48v) plugin [47] and the fraction of growing cells was 
expressed as a percent of untreated control as described by 
Franken et al. [48].
Cell lysis and immunoblotting 
Cells were lysed on ice for 30 min in RIPA 
buffer (CST, UK) containing protease and phosphatase 
inhibitor cocktails (Sigma, UK). Lysates were clarified 
by centrifugation (13,000 rpm, 15 min, 4°C), diluted with 
Laemmli buffer, and denatured at 95°C for 5 min. SDS-
PAGE and immunoblotting were performed according to 
standard protocols [49]. Most primary antibodies used 
were from CST, BAG-1 (3.10 G3E) was from Santa Cruz 
Biotechnology, and β-actin-HRP was from Sigma (UK). 
HRP-conjugated secondary antibodies were from Dako 
(Denmark). Proteins were detected by SuperSignal West 
Pico or Fempto chemiluminescent substrate (Thermo 
Scientific, UK) using a BioRad Fluor-S Multiimager with 
Quantity One 1-D v4.6.6 image acquisition and analysis 
software.
FACS analysis
For cell cycle analysis, cells were processed as 
described before [35]. DNA content was determined by 
capturing 20,000 events using a FACSCalibur (Becton 
Dickinson) flow cytometer following the manufacturer’s 
instructions. The proportion of cells in different phases of 
the cell cycle was analyzed with ModFit LT v4.1.7 and 
expressed as a percentage of total cells.
Metabolic labelling
Tran35S-Label (MP Biomedicals, Illkirch, France) 
was added to the culture medium (0.37 MBq/ml) for 
the final 2 h of culture. Cells were lysed in RIPA buffer 
with protease inhibitors. Lysates were supplemented 
with 10 mg/ml L-cysteine and 10 mg/ml L-methionine, 
clarified by centrifugation, applied onto Whatmann filter 
discs (GE Healthcare, UK), and air dried. Bound proteins 
were precipitated by 10% (w/v) trichloroacetic acid 
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(Sigma, UK). Boiling 5% (w/v) trichloroacetic acid was 
added to the filter discs before washing in absolute ethanol 
and acetone. The filter discs were air-dried, immersed 
in OptiScint ‘HiSafe’ scintillation fluid (PerkinElmer, 
UK) and radioactivity was measured using a WALLAC 
1409 liquid scintillation counter (PerkinElmer, USA). 
Control cells were treated with cycloheximide (10 µg/ml). 
Counts from cycloheximide-treated samples were 
subtracted from experimental values and the difference 
was expressed as a percentage of untreated cells.
Tumor xenografts and immunohistochemistry
NOD.SCID mice (Harlan Laboratories, UK) 
were bred and maintained locally under pathogen-free 
conditions. Animal experiments were approved by the 
local ethical committee and performed under Home 
Office license PPL30/2964. Two days before tumor 
cell injection, female animals were offered ad libitum 
doxycycline-containing (200 μg/ml) water for induction 
of myc-BAG-1S expression or plain water as control. For 
tumor implantation, SKBR3 Tet-On myc-BAG-1S cells 
were mixed 1:1 with BD Matrigel basement membrane 
matrix (SLS, UK). Cell suspensions (5 × 106 cells/mouse) 
were injected subcutaneously into the mammary fat pad 
and allowed to form xenografts over 32 days. Tumors 
were measured by callipers, weighed, and cryopreserved 
in OCT buffer (CellPath, UK). Haemmatoxylin and eosin 
(H & E) staining was performed as previously described 
[50] and immunohistochemical detection was performed 
using ImmPress HRP polymer detection reagent (Vector 
Laboratories, UK) according to the manufacturer’s 
instructions. Sections (5 μm) were mounted and were 
imaged using an Olympus digital microscopy/slide 
scanning system (Olympus Soft Imaging Systems, 
Germany) with a x40 objective with dotSlide v2.2 
software. Immunoreactivity was assessed in a blinded 
manner by a consultant histopathologist (MAK).
Statistical analysis
For comparisons between groups, statistical 
significance (p < 0.05) was determined by unpaired t-test 
assuming unequal variances or by one-way or two-way 
ANOVA with Holm-Sidak multiple comparisons test using 
GraphPad Prism version 6.03 for Windows, GraphPad 
Software, La Jolla California USA. Drug combination 
indexes were calculated using Biosoft’s CalcuSyn v2.11 
[51]. Kaplan-Meier analysis was performed with IBM 
SPSS Statistics v22, while immunoblot densitometric 
analysis with Image J v1.48.
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